touchINFECTIOUSDISEASES caught up with Craig Hoesley (Division of Infectious Diseases, University of Alabama School of Medicine, Birmingham, Alabama, US) to discuss the phase 1 trial investigating intrarectal dapivirine gel for HIV prevention.
Part 1 of our discussion can be viewed here.
His abstract entitled: ‘A randomized, double blind, placebo-controlled, phase 1 safety and pharmacokinetic study of dapivirine gel (0.05%) administered rectally to HIV-1 seronegative adults (MTN-026)’ (OA16.05) was presented at the HIVR4P Virtual Conference 2021, 03 February 2021.
Questions:
- What clinical evidence supports the development of an intrarectal formulation of dapivirine? (0:11)
- Could you tell us a little about the design and inclusion criteria of the MTN-026 study? (1:33)
- What were the findings of the study in terms of safety, pharmacokinetics and acceptability? (2:24)
- What will be the next steps in the clinical development of intrarectal dapivirine? (4:54)
Disclosures: Craig Hoesley has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of HIVR4P Virtual Conference 2021.
